Release
2024/04/19
New data from the largest European real-world evidence study of cefiderocol demonstrate positive outcomes including high rates of clinical success and day 28 survival across Gram-negative pathogens considered as critical priorities by the WHO in patients with limited treatment options1,2
OSAKA, Japan, APRIL 19, 2024 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data from the largest European real-world evidence study (PERSEUS) of Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, for the treatment of critically ill patients with carbapenem-resistant (CR) Gram-negative (GN) bacterial infections at the 34th ESCMID Global (formerly ECCMID) in Barcelona, 27–30 April, 2024.
Please see below under About Cefiderocol for full indications of Fetroja in the U.S.
The PERSEUS study is a retrospective, multicenter, observational chart review study designed to describe the efficacy and safety of real-world cefiderocol use in adult patients with GN bacterial infections.1 The analysis found patients receiving cefiderocol achieved an overall clinical success rate (primary endpoint, defined as the composite of clinical cure and/or survival at Day 28) of 84.3% and a 28-day all-cause mortality of 21.5%.1
The majority of patients had respiratory tract infections (47.9%) caused by Pseudomonas aeruginosa (66.7%), Klebsiella pneumoniae (10.0%) and Stenotrophomonas maltophilia (7.7%) as principal pathogens. Additionally,19.5% of patients had polymicrobial infections.1
The study included 261 critically ill adult patients with limited treatment options who received cefiderocol for less than 28 days as part of Shionogi’s Early Access Program in Spain. Of these, 64.8% were resistant to all tested antibiotics and 44.4% experienced treatment failure with prior antibiotics.1 The patients received cefiderocol consecutively for ≥72 hours for a confirmed GN bacterial infection. The patients included in the analysis were critically ill with nearly two-thirds (63.2%) in the intensive care unit, 47.1% on mechanical ventilation and 28% with septic shock.1 In addition to GN bacterial infections, patients also had serious comorbidities including immunosuppression (30.3%), solid or hematological tumors (23.8%), diabetes (22.2%), transplant (20.7%), chronic renal disease (13.0%) and chronic obstructive pulmonary disease (10.3%).1
Across these 261 patients, cefiderocol was generally well tolerated with six patients experiencing an adverse drug reaction.
Dr. Alex Soriano, Head of Infectious Diseases Service at Hospital Clinic in Barcelona, says: “The increasing resistance of Gram-negative bacterial infections to current therapies makes them difficult to treat. Real-world evidence is particularly important when reviewing antibiotic use for multidrug-resistant pathogens because of the challenges of conducting randomized clinical trials. These new data reinforce the importance of cefiderocol and contribute to the growing body of real-world evidence in patient care for those with difficult-to-treat pathogens that were resistant to other antibiotics.”
Isao Teshirogi, Ph.D, Chief Executive Officer of Shionogi, adds: “Shionogi is proud of its 60-year leadership in developing anti-infective medicines and we remain committed to our focus on innovative research that may help address the growing threat of antimicrobial resistance. Cefiderocol is included in the World Health Organization’s 23 Model List of Essential Medicines6, and these data demonstrate its continued importance in helping to improve outcomes for patients with some of the most difficult to treat infections.
We also know how important it is to ensure equitable, global, access to essential medicines like cefiderocol. That’s why we are working with like-minded partners GARDP and CHAI, to support the availability of this important antibiotic for people living in low- and middle-income countries.”
About Shionogi & Co. Ltd.
Shionogi & Co., Ltd. is a 146-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en.
About Shionogi in AMR
Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years. Shionogi is proud to be one of the few large pharmaceutical companies that continues to focus on R&D in anti-infectives.
About Cefiderocol
In Europe, cefiderocol is commercially available under the brand name Fetcroja® for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.[1] In the U.S., cefiderocol is available under the brand name Fetroja® and is indicated in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia (HABP/VABP) and complicated urinary tract infections (cUTIs) caused by certain susceptible Gram-negative microorganisms.[2] In Japan, cefiderocol is commercially available under the brand name Fetroja® and received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for various infections caused by strains resistant to carbapenem antibiotics among sensitive strains of Escherichia coli, Citrobacter species, Klebsiella pneumoniae, Enterobacter species, Serratia marcescens, Proteus species, Morganella morganii, Pseudomonas aeruginosa, Burkholderia species, Stenotrophomonas maltophilia, and Acinetobacter species.[3]
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
SEU Press Office: pressoffice@shionogi.eu
U.S. Media Contact: ShionogiCommunications@shionogi.com
References
[1] Ramirez P et al. Real-world effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections in the early access programme in Spain: results of the PERSEUS study. Abstract. ECCMID 2024.
[2] World Health Organization. WHO priority pathogens list for R&D of new antibiotics. Available at: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed: March 2024.
[3] Fetcroja® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf . Accessed: March 2024.
[4] Fetroja® Prescribing information. Available at: https://www.shionogi.com/content/dam/shionogi/si/products/pdf/fetroja.pdf. Accessed: April 2024.
[5] Press release on November 30, 2023. Regarding the Acquisition of Manufacturing and Marketing Approval for the New Siderophore Cephalosporin Antibiotic FetrojaⓇ(cefiderocol) Intravenous Infusion 1g vial in Japan
[6] WHO Model List of Essential Medicines - 23rd list, 2023. WHO Model List of Essential Medicines - 23rd list, 2023 Accessed: April 2024